ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 852

C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis

Xiaochun Liu1, Maureen D. Mayes1, John D. Reveille2, Emilio B. Gonzalez3, Brock E. Harper4, Hilda T. Draeger5 and Shervin Assassi6, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, 3Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 4Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, 5Med/Clinical/Immunology, Univ of TX Health Sci Ctr, San Antonio, TX, 6Rheumatology, Univ of Texas Health Science Houston, Houston, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: C-reactive protein (CRP) and scleroderma

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

ABSTRACT:

Background/Purpose: The currently available clinical markers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In a previous study conducted in the GENISOS (Genes versus Environment in Scleroderma Outcome Study) cohort, none of the baseline clinical variables (including serology and disease type) was predictive of long-term decline in forced vital capacity (FVC). Elevated C-reactive protein (CRP) levels have been reported in a subset of patients with SSc and correlated with disease severity as well as shorter survival. Herein, we examine the predictive significance of CRP for progression of ILD (based on longitudinally obtained serial FVC) and survival in a large early SSc cohort.    Methods: We compared the plasma CRP levels in 266 SSc patients enrolled in the GENISOS cohort (mean disease duration at enrollment 2.5 years, 59% diffuse cutaneous involvement) to that of 97 age, gender and ethnicity-matched controls. Subsequently, the correlation between the plasma CRP levels and concomitantly obtained markers of disease severity was assessed. The primary outcome was decline in FVC over time. A total of 1,016 FVC measurements fulfilled the American Thoracic Society/European Respiratory Society criteria and were included in the analysis. The mean follow-up time was 4.4 years. The predictive significance for long-term change in FVC was investigated by a joint analysis of longitudinal measurements (sequentially obtained % predicted FVC) and survival data. This approach allows inclusion of all FVC measurements and accounts it for survival dependency.  Results: We confirmed that the baseline plasma CRP levels were significantly higher in SSc patients than matched controls (p=0.027). In addition to body mass index and age at baseline, the plasma CRP levels were associated with absence of anti-centromere antibodies (p=0.043). Also consistent with previous reports, plasma CRP levels correlated with the concomitantly obtained joint, skin and lung components of the Medsger Severity Index, as well as, FVC, DLco, mRSS. More importantly, baseline CRP levels correlated with shorter survival (p<0.001) and predicted the long-term decline in % predicted FVC (β= -0.35, 95% CI: -0.61 - -0.09, p= 0.006).  The predictive significance of CRP for ILD progression was independent of potential confounders (age at baseline, gender, ethnicity, body mass index, and treatment with immunosuppressive agents) in the multivariable model (β= -0.37, 95% CI: -0.63 – -0.11, p=0.005).

Conclusion: In the present study, we show for the first time that the baseline CRP levels are predictive of long-term ILD progression. High CRP levels can identify the subgroup of patients that would benefit from more intensive monitoring and treatment.

 


Disclosure:

X. Liu,
None;

M. D. Mayes,
None;

J. D. Reveille,
None;

E. B. Gonzalez,
None;

B. E. Harper,
None;

H. T. Draeger,
None;

S. Assassi,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/c-reactive-protein-predicts-long-term-progression-of-interstitial-lung-disease-and-survival-in-patients-with-early-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies